Comparing vision and macular thickness in neovascular age-related macular degeneration, diabetic macular oedema and retinal vein occlusion patients treated with intravitreal antivascular endothelial growth factor injections in clinical practice.
Rajya L GurungLiesel M FitzGeraldBennet J McComishAlex W HewittNitin VermaKathryn P BurdonPublished in: BMJ open ophthalmology (2021)
At the end of 12 months, nAMD and RVO cohorts had the greatest improvement in BCVA, however the final BCVA for DMO was significantly better than for nAMD.